10 520820 Jun 0106

WWR:jam 6/6/06 522226 E-223-2002/0-US-03 PATENT

Attorney Reference Number 4239-66646-06 Application Number 10/526,820

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Joel Moss et al.

Application No.: 10/526,820

Filed: March 3, 2005 Confirmation No.: 5471

For: FACTORS THAT BIND INTESTINAL

TOXINS

Examiner: To be assigned

Art Unit: 1617

Attorney Reference No.: 4239-66646-06

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP 16, DIRECTOR OF THE U.S. PATENT AND TRADEMARK OFFICE, P.O. Box 1450, Alexandra, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)____

Date Mailed June 6, 2006

MAIL STOP 16
DIRECTOR OF THE U.S. PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

REQUEST FOR REFUND UNDER 37 C.F.R. § 1.26

Applicants hereby request a refund of \$1,250.00 for the excess claims fees improperly charged by the U.S. Patent and Trademark Office (USPTO) to Deposit Account No. 02-4550 in connection with the above-referenced application.

The amount of \$1,350.00 was charged to Deposit Account No. 02-4550 on November 8, 2005, as shown in a highlighted manner on the attached November 30, 2005 Deposit Account Statement (Exhibit A). It appears that this charge is for extra claims fees for the application. This charge is erroneous in view of the following facts:

Applicants filed this application on March 3, 2005, with a Preliminary Amendment to reduce the number of claims, among other things. A copy of the original patent application Transmittal Letter showing the total number of claims filed with this application is attached as **Exhibit B**. A copy of the Preliminary Amendment filed with the application, showing amendments to the claims, is attached as **Exhibit C**. It appears that the filing fees were

calculated by the USPTO <u>prior</u> to entry of the Preliminary Amendment, and thus the charge to the deposit account was incorrectly made. As indicated on the Transmittal Letter, this application was amended upon filing to include 49 total claims and three independent claims. Therefore, the filing fee submitted with the application (\$2,750.00 plus \$40.00 recordation fee, totaling \$2,790.00) is correct. No additional charges were required. Applicants therefore request a refund of the miscalculation of claims fees, totaling \$1,350.00.

Please mail the refund to the undersigned agent, or credit the refund to Deposit Account No. 02-4550. A copy of this document or paper is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Rv

Wayne W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446



United States Patent and Trademark Office

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MONTHLY STATEMENT OF DEPOSIT ACCOUNT

To replenish your deposit account, detach and return top portion with your check. Make check payable to Director of Patents & Trademarks.

KLARQUIST SPARKMAN CAMPBELL LEIGH & WHIN FINA ACCOUNTING
121 S.W. SALMON STREET
SUITE 1600
PORTLAND OR 97204

Account N	la.	
02	4550	
Date		
11	-30-05	
Page		
	1	

PLEASE SEND REMITTANCES TO: U. S. Patent and Trademark Office P.O. Box 70541 Chicago, IL 60673

	E PO		CONTROL NO.	DESCRIPTION (Serial, Patent, TM, Order)	, DOCKET NO.		FEE CODE	CHARGES/ CREDITS	BALANCE
111	1	05	1	78675151	6592-71140-1	2/LMC:GH	8507	15.00	19482.08
lii	li	05	182	10551571		71851-01	8021	40.00	
li i		05	218	10554493		72353-01	2631	150.00	
lii		05	219	10554493		72353-01	2642	200.00	
lii		05	220	10554493		72353-01	2633	100.00	
lii		05	221	10554493		72353-01	2615	150.00	
lii		05	1249	78744297		4-01/ALW	7007	275.00	
lii		05	1251	78744298		5-01/ALW	7007	275.00	
lii		05	1581	2303621	7347-7151		7205	100.00	
m		05	1582	2303621	7347-7151		7208	200.00	
lii.		05	2	10962191		-6078-03	1806	180.00	17812.08
11		05	207	78671777	6592-71599-0		8507	15.00	
lii		05	522	78744792		72247-01	7007	275.00	
lii.		05	1	10785203		70332-02	1806	180.00	
11		05	3	60692845	• • •		8021	40.00	17302.08
11	3	05	9	75350443			9204	-100.00	
11		05	19	11191618	7276-	70212-02	8021	40.00	
11		05	46	10535523	• •		8021	40.00	17322.08
11		05	50	10535523			8021	40.00	
11		05	51	11134703	4239-	67015-05	8021	40.00	17242.08
11		05	54	10535523	6395-	66741-06	8021	40.00	17202.08
11		05	18	78424853		71617-02	7402	300.00	16902.08
11		05	19	78424853	7347-7161		7402	300.00	16602.08
11		05	26	10996184		71612-01	1201	200.00	16402.08
11		05	27	10996184	612-	71612-01	1202	50.00	16352.08
11		05	28	10996184	612-	71612-01	1252	450.00	15902.08
11		05	143	09948821		82-61170	1814	130.00	
11		05	910	78209176		64409-01	7004	450.00	
11		05	3	PCT/US05/33708		- 1	9204	-700.00	
11		05	20	5484470	7276-	72044-01	2552	1150.00	
11		05	21	5484470		72044-01	1558	1640.00	
iil		05	22	78671777	6592-71599-0		8507	15.00	
iil	از		123	11191618			9204	-60.00	
iil	7		269	11265675	7273-	70679-02	2011	150.00	
iil		05	270	11265675		70679-02	2111	250.00	
iil		05	271	11265675		70679-02	2311	100.00	
	1		-, .		,-,,				
	A	N	MOUNT S	SUFFICIENT TO	OPENING BALANCE	TOTAL CHAP	RGES	TOTAL CREDITS	CLOSING BALANCE
(ICES REQUESTED					<u></u>

MENOPIAL MACOOM

MUST ALWAYS BE ON DEPOSIT

EXHIBIT

BEST AVAILABLE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

MONTHLY STATEMENT OF DEPOSIT ACCOUNT

To replenish your deposit account, detach and return top portion with your check. Make check payable to Director of Patents & Trademarks.

KLARQUIST SPARKMAN CAMPBELL LEIGH & WHIN FINA ACCOUNTING 121 S.W. SALMON STREET SUITE 1600 PORTLAND OR 97204

Account No.				
•	024550	-		
Date				
	11-30-05			
Page				
	2	ĺ		

PLEASE SEND REMITTANCES TO: U. S. Patent and Trademark Office P.O. Box 70541 Chicago, IL 60673

*** O.D. INDICATES OVERDRAWN

DA	TE PO	STED	CONTROL	DESCRIPTION	DOCKET NO.	FEE	CHARGES/	BALANCE	
	DAY		NO.	(Serial, Patent, TM, Order)		CODE	CREDITS		
	<u>`</u> '	05	272	11265675	7273-70679-02	2202			
	8	95. 95	2	10526820 10526820	1.259 = 666 H5 506	216 m	MANAGEMENT OF THE PARTY OF STREET, SALES		
			102	11181668	12397 500 161 666	2011	7 2 2 3 3 5 0 NO C		
∐i			103	11181668			150.00		
- li			104	11181668		2051 2111	65.00		
li.			105	11181668			250.00		
li.			106	11181668		2311 2202	100.00		
li.			290	60733327	7272_72262_01		125.00		
٦į.		05	513	10555408	7273-72343 - 01 2847-72452 - 01	2005 2631	100.00		
- li		05	514	10555408	2847-72452-01	2633	150.00		
l'i		05	515	10555408	2847-72452-01	2642	200.00		
li:		05	516	10555408	2847-72452-01 2847-72452-01	8021			
lii	- 1		11	E-REPLENISHMENT	204/-/2452-01		40.00		
			75	10347542	11001-006-99	9203			
	_	05	87	60684491	160-70957-01	2251 8021	60.00		
111			124	78749463	4502-72520-01		40.00		
	1 -	05	182	60577283	6592-72530-01 160-68644 - 02	7007	275.00		
lii		05	209	10319018		8021	80.00	1 - 1	
- ; ;	-	05	232		1011-62960	1251	120.00		
	_	05		60659513	4239-68725-01	8021	40.00		
lii	_		291	PCT/US05/13236	1505 (7000)	8021	40.00	1 - 1	
			2	10719885	1505-67088	1811	100.00		
			134	10518956	(0.35 -3.4	8021	40.00		
11		- 1	350	78750509	332-68377-01/ALW	7007	275.00		
111			355	78750512	332-68378-01/ALW	7007	275.00		
11			362	78750515	332-72282-01/ALW	7007	275.00		
11		05	391	78750536	7347-72262-01/RJP	7001	975.00		
[]]	10		615	78750656	332-68379-01/ALW	7007	275.00		
11	10		1669	78751180	6592-72601-01	7007	275.00		
11		05	103	11181668		2202	-125.00		
11		05	104	11181668		2201	100.00		
111		05	105	11181668		2202	25.00		
111		05	106	11181668	_	2251	60.00		
[1]		05	116	10554143	7126-72225-01	8021	40.00		
11		05	121	11261069	7291-71804-01	8021	40.00	16437.08	
11	14	05	123	10554139	7126-72254-01	8021	40.00	16397.08	
\vdash	<u></u>	N A	AMOUNT S	SUFFICIENT TO	OPENING BALANCE TOTAL CHA	RGES T	TOTAL CREDITS T	CLOSING BALANCE	
	COV	'ER	ALL SERV	ICES REQUESTED		- 1			
1				BE ON DEPOSIT		- 1			
****	M5020B (6/2004)								

MS020B (6/2004)



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MONTHLY STATEMENT OF DEPOSIT ACCOUNT

To replenish your deposit account, detach and return top portion with your check. Make check payable to Director of Patents & Trademarks.

KLARQUIST SPARKMAN CAMPBELL LEIGH & WHIN FINA ACCOUNTING
121 S.W. SALMON STREET
SUITE 1600
PORTLAND OR 97204

Account No.					
į ,	024550				
Date					
	11-30-05				
Page					
	3				

PLEASE SEND REMITTANCES TO: U. S. Patent and Trademark Office P.O. Box 70541 Chicago, IL 60673

*** O.D. INDICATES OVERDRAWN

DA	TE	POSTI	CONTROL	DESCRIPTION		FEE	CHARGES/	
МС	D. D.	AYY	R. NO.	(Serial, Patent, TM, Order)	DOCKET NO.	CODE	CREDITS	BALANCE
T		40		60734814		2005	100.00	16297.08
11		4 0		60700964	4550-70903-01/RJP	8021	40.00	
11		4 0		PCT/US05/24529	3533-67309-02	8021	40.00	16217.08
]11		5 0		11191618		9204	-250.00	
11		5 0		10652295	6565-66784-01	1251		
-[11		5 0		78753559	6592-72142-01	7007		
11		5 0		78754082	2747-72644-01/KSK	7001		
111		6 0		10237567	SALKINSO44CP	2814		
11		6 0		10533477	6682-66959-02	1632		
11		6 0		11272966	,	9204		
11		6 0		11183271		9204		
111	1	6 0 9	69	2464798	7319-47802-01/RAK	8521		
11			233	4704876	158-8677	8021		
111	1	6 0	814	78754681	7347-72650-01/LMC	7001		
11	1	وه 7	5 1	10851755	6454-68419-01	1202		
111	1	7 0	32	5084291	158-8677	8021	200.00	
111	11	7 0	64	E-REPLENISHMENT	,50 50,,	9203		
111	[1]			10616122	0140022US	2252		
111	1			11157473	2242-69454-01	8021	40.00	
11	118			10237567	SALKINS044CP	2252		
111	118	B 05		5293803	158-8677	8021	40.00	
111	11			10001268	6395-61264	1251	120.00	
11	118			10001268	6395-61264	1806	180.00	22337.08
111	118			09989946	0,5,5 0,204	9204	-300.00	
11	118			10871805		9204	-300.00	
11	18			10884514		9204	-300.00	,
11	18			10871960	•	9204	-300.00	
111	118			5293803	158-8677	8021	40.00	
111	18			10305800	190 00//	8021	40.00	
11	18			10305800	4239-63964-01	8021	40.00	
lii	18			78756460	6431-72664-01	7001		
lii	18			78756465	6431-72663-01	7001	1950.00	
lii	21			10467684	5578-66536/RJP		650.00	20817.08
11	21			11281044		2201	100.00	20717.08
	21		61	11281044	7172-70319-02	2011	150.00	20567.08
11			62	11281044	7172-70319-02	2111	250.00	20317.08
''	21	د ا	02	11201044	7172-70319-02	2311	100.00	20217.08
	_	AN.	AMOUNT S	SUFFICIENT TO	OPENING BALANCE TOTAL CHAP	RGES	TOTAL CREDITS	CLOSING BALANCE
'				ICES REQUESTED		- 1	į	
	M	UST	ALWAYS	BE ON DEPOSIT	1	1		



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MONTHLY STATEMENT OF DEPOSIT ACCOUNT

To replenish your deposit account, detach and return top portion with your check. Make check payable to Director of Patents & Trademarks.

KLARQUIST SPARKMAN CAMPBELL LEIGH & WHIN FINA ACCOUNTING
121 S.W. SALMON STREET
SUITE 1600
PORTLAND OR 97204

The State of the S

Accou	int No.
1	024550
Date	
	11-30-05
Page	
	4

PLEASE SEND REMITTANCES TO: U. S. Patent and Trademark Office P.O. Box 70541 Chicago, IL 60673

*** O.D. INDICATES OVERDRAWN

DATE POST		DESCRIPTION (Serial, Patent, TM, Order)	DOCKET NO.	FEE	CHARGES/	BALANCE
MO. DAY	in.			CODE	CREDITS	
	05 63 05 64		7172-70319-02		, , ,	
	76		7172-70319-02			
1 1 1				8021		
				8021		
			7346-72678-01	7001	7-2	
	740		131-70598-01	7001		
	05	1 ''-''	6541-63376	1251		
11 22 0			3533-69199-03/JBH:MLB	8007		18142.08
	219		1011-69479-02	8021		17982.08
	943		7118-72667-01	7001		
	1785	,	7347-72017-01/RJP	7205	100.00	17557.08
	1786	1	7347-72017-01/RJP	7201	400.00	
	1787		7347-72017-01/RJP	7206		17057.08
11 22 0			7347-72017-01/RJP	7203	100.00	
11 23 0			6235-70161-01/SLR:DM	8007	20.00	
11 23 0		78565879	7347-72255-01/LMC	8521	40.00	
11 23 0		78565879	7347-72255-01/LMC	8522		
11 23 0		76599302	7115-69136-01/DPP/RJP	6006	100.00	
11 23 0		11281044	7172-70319-02	8021	40.00	
11 23 0		78759678	3720-72682-01/JEG	7001	325.00	
11 25 0		60706129		8021	40.00	
11 25 0		76599302	7115-69136-01/DPP/RJP	6006	-100.00	
11 25 0		78760673	131-72669-01	7001	325.00	
11 25 0		78760677	131-72670-01	7001	325.00	
11 28 0		0616696	,==,,==	6205	100.00	
11 28 0	5 7	0616696		6201	400.00	
11 28 0	5 21	2963032	7204-68462-02/LMC:TH	6212	100.00	
11 28 0	5 23	29175852	7231-70187-01	2253	510.00	
11 28 0		10406912	6541-65600	1801	790.00	13892.08
11 28 0		11084408	9711 03000	8021	40.00	13852.08
11 28 04		60716807	4239-69494-01	8021	40.00	
11 28 04	5 119	60716807	4239-69494-01	8021		13812.08
11 28 05		09892350	4233-63434-01 MLF-600-13	2801	40.00	13772.08
11 28 05		60547328	71E1 000-13	8021	395.00	13377.08
11 28 05		60547328		8021	40.00	13337.08
11 28 05	303	PCT/US05/06396	[8021	40.00	13297.08
		. = 1, 2005, 00530		0021	40.00	13257.08
AN	AMOUNT	SUFFICIENT TO	OPENING BALANCE TOTAL CHAI	PCEC 1	TOTAL COEDIZO	
COVE	R ALL SERV	ICES REQUESTED	OTAL CHAI	משפט	TOTAL CREDITS	CLOSING BALANCE
MUS	TALWAYS	BE ON DEPOSIT				
S020B (6/200					** OD INDICAT	ES OVERDRAVAIN

7

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MONTHLY STATEMENT OF DEPOSIT ACCOUNT

To replenish your deposit account, detach and return top portion with your check. Make check payable to Director of Patents & Trademarks.

KLARQUIST SPARKMAN CAMPBELL LEIGH & WHIN FINA ACCOUNTING
121 S.W. SALMON STREET
SUITE 1600
PORTLAND OR 97204

Account No.			
024550			
Date	\neg		
11-30-05			
Page			
5			

PLEASE SEND REMITTANCES TO: U. S. Patent and Trademark Office P.O. Box 70541 Chicago, IL 60673

DAT	F P	OSTED	1						
MO.	DA'	Y YR.	NO.	DESCRIPTION (Serial, Patent, TM, Order)	DOCKET NO.		FEE CODE	CHARGES! CREDITS	BALANCE
		05	328	11152495			8021	40.00	13217.08
		05		5718435		-44437-01	8021	40.00	
[]]	28	-	484	6126170	5026	-44437-01	8021	40.00	
	28		485	6367809	5026	-44437-01	8021	40.00	
11	28		488	PCT/US05/11086			8021	40.00	
11	28		489	PCT/US50/11086			8021	40.00	1 2 2 1
111	28		566	10511362		İ	8021	40.00	
11		05	8	10697965	050005-000158.L	SP.265218	2201	100.00	
[]]		05	9	10697965	050005-000158.L		2202	25.00	
		05	13	09995327	6	541-60971	1251	120.00	
111		05	23	10697848	050005-000145.L	SP.245951	1806	180.00	
11		05	776	2016147		-69764-01	7205	100.00	
111		05	777	2016147	7194-	-69764-01	7201	400.00	
		05		STACEY C. SLATE			9204	-266.00	12318.08
		05	113	60706562	7180-	-70877-01	8021	40.00	
111	30	05	114	11200692		1	8021	40.00	
			J						
		1 1			•	1	1		
1 1			1				-		
		1				1	ľ		
			ļ			į	* 1		
1 1				ì			ľ		
1 1			1			ł			
		- 1	1						·
				l					i
	ı						l		
		- 1	ł			j	ř		
	ı		i	ľ		İ	i		
1 1	1	- 1		1					<u> </u>
1 1	- 1		j		•				
		- 1		}					[
		- 1	ĺ			j			
1 1	- 1		1			ĺ			
1 1	- 1	-	i i	1		i	Ţ		1
1 1		- 1	İ			j	ľ		<u> </u>
	- {	- 1	j	İ					
$\vdash \perp$	ᅷ		MOUNT	USE LOUENT TO	Long.			[
_	A VV	IN A	MOUNT S	UFFICIENT TO	OPENING BALANCE	TOTAL CHAR	GES 1	OTAL CREDITS	CLOSING BALANCE
	יונ <i>א</i>	CT /	ALL DERVI	CES REQUESTED BE ON DEPOSIT	1 30105 -0				Į.
MS020			VIANW 19 F	· . · · · · · · · · · · · · · · · · · ·	19497.08	30680.00		23421.00 1	2238.08
	. 10/.			i visi i iz siiki Sukhila is	egi ragan 🕍 egi		**	* O.D. INDICATE	S OVERDRAMM

EXPRESS MAIL LABEL NO. EV510808334US DATE OF DEPOSIT: March 3, 2005

ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 4239-66646-06 DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 C.F.R. § 1.5) CONCERNING A NATIONAL STAGE FILING UNDER 35 U.S.C. § 371 Not yet assigned INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US2003/028282 September 9, 2003 September 10, 2002 TITLE OF INVENTION FACTORS THAT BIND INTESTINAL TOXINS APPLICANT(S) FOR DO/EO/US Joel Moss and Masatoshi Noda Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371. This is an express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(1). Items 5, 6, 9 and 21 indicated below are submitted to make this express request. The United States has been elected in a Demand for International Preliminary Examination (Article 31). 5. A copy of the International Application as filed (35 U.S.C. § 371(c)(2)) a.
is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. \(\subseteq \) is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English-language translation of the International Application (35 U.S.C. § 371(c)(2)). a.
is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau to the United States Receiving Office). b. I have been communicated by the International Bureau. c. A have not been made; however, the time limit for making such amendments has NOT expired. d. A have not been made and will not be made. 8. An English-language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. § 371(c)(4)). An English-language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 10. (35 U.S.C. § 371(c)(5)). Items 11 to 21 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98. 12. 🛛 An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 and the Recordal fee of \$40.00 are included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 C.F.R. § 1.76. 15. A substitute specification. Powers of attorney from the inventors. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. §§ 1.821 - 1.825. 18. A second copy of the published International Application under 35 U.S.C. § 154(d)(4). A second copy of the English-language translation of the international application under 35 U.S.C. § 154(d)(4). 20. Other items or information: Abstract on a separate page. Written Opinion. Preliminary Examination Report. International Search Report. Copy of Reference Cited.

EV510808334US_



EXPRESS MAIL LABEL NO. EV510808334US DATE OF DEPOSIT: March 3, 2005

Not yet assi	igned		r.k. y 1,5)	PCT/US2003/028				9-66646-06	NUMBER
The following	g fees are	submitted:							
_	21. Separational fee Superstanding fee Superstanding fee								
22. Examination fee If international preliminary examination around his USDTO and all abstract at the second present and all abstract at the second present at the second prese								100.00	
If international preliminary examination report prepared by USPTO and all claims satisfy novelty, nonobviousness (inventive step) and utility (industrial applicability) i.e., provisions of PCT Article									
33(1)-(4)									
All other	r situation	is	······································			\$200	<u></u>		<u></u>
23. Search for		F.R. 1.445(a)	V2)) has been r	oaid on the international ap	mliandina en e	ha LICDTO	\$	100.00	
an Internation	nal Searcl	ning Authori	ty			\$100			•
Internation	onal Sear	ch Report pr	epared and pro	vided to the Office		\$400	}		
All other	rsituation	15	***********************				-		
☐ Addition	al fee for	enecification	and descine	filed in paper over 100 sh		21, 22, and 23 -	\$	500.00	
listing or	compute	r program lis	ting filed in el	ectronic medium). The fe	eeus (excludi e is \$250 for	ng sequence each additional			
50 sheets	of paper	or fraction t	hereof.				}	ľ	
Total Sheets	s Ex	tra Sheets	Number of	each additional 50 or fract	ion thereof	RATE	1		
- 100		0.460	,,,	ound up to a whole numbe	"		ļ		
62 - 100	'	0/50=		0		x \$250	S	0.00	
							 		
claimed prior	1 30.00 its	ior lumishin; 37 C F R & 1	g the oath or do	eclaration later than 30 mo	nths from the	e earliest	\$	0.00	
		<u> </u>					<u> </u>		
CLAI			BER FILED	NUMBER EXTRA		RATE	<u> </u>		
Total claims		+	- 20 =	29	x \$50.00		5	1,450.00	·
Independent			-3 =	4	x \$200.0		\$	800.00	<u> </u>
MULTIPLE	DEPEN	DENT CLA	IM(S) (if appli		+ \$360.0		\$	0.00	
Padueti	on of 1/2	for filing by	TOT	AL OF ABOVE CA	LCULA'	TIONS =	\$	2,750.00	
Reducti	On OI 1/2	tor tilling by	small entity.	Small entity status is claim	ed for this a	pplication.	\$	0.00	
					SUBT	OTAL =	\$	2,750.00	
Processing i	ice of \$13	0.00 for furt e (37 C F R	iishing the Eng §§ 1.492(f)).	lish translation later than	30 months fr	om the earliest	\$	0.00	
			18 1.472(1/).	TOTAL N	ATTONA	I. KER =	S	2,750.00	
Fee for reco	rding the	enclosed ass	ignment (37 C	F.R. 6 1.21(h)). The assi	propert much	he	\$	40.00	
accompanie	d by an a	ppropriate co	over sheet (37 (C.F.R. §§ 3.28, 3.31). \$40	.00 per prop	erty. +	<u> </u>	10.00	
				TOTAL FE	ES ENCL	OSED =	\$	2,790.00	
							refun	ded	\$
					_		Amo	unt to be ged	\$
a. ⊠ Ac	hack in th	se amount of	F 2 700 00 +=	cover the above fees is en					
b.☐ Plea	ase charg nclosed.	e my Deposi	t Account No.	in the amount of \$	to co	ver the above fees	. A dı	plicate copy of	this sheet
		:- .	ا بد د د د						
C. LOU INC	The Director is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.								
NOTE: Wh	E: Where an appropriate time limit under 37 C.F.R. § 1.494 or § 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
	(0))	oe ince and	. B. anica (0 ()	rator e me apprication to	henging som		//		
						//	/ \	- (
SEND ALL CORRESPONDENCE TO THE ADDRESS ASSOCIATED WITH									
	CICNATE INC.								
CUSTOMER NUMBER 36218									
Susan Alpert Siegel, Ph.D. KLARQUIST SPARKMAN, LLP NAME									
One	World T	rade Center,							
		mon Street 97204-2988				43,121 EGISTRATION	NI DA	OED .	
. 01.						COBTATION	MOM	אטפ	

cc: Docketing

The state of the s

SAS:gte 03/03/05 4239-66646-06 360171.doc PATENT EXPRESS MAIL LABEL NO. EV510808334US DATE OF DEPOSIT: March 3, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moss et al.

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

For: FACTORS THAT BIND INTESTINAL

TOXINS

Examiner: Not yet assigned Art Unit: Not yet assigned

Attorney Reference No. 4239-66646-06

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV510808334US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent

for Applicant(s

Date Medical

March 3, 2005

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced patent application, please amend the application as follows:

Amendments to the Specification begin on page 2.

Amendments to the Claims are reflected in the listing of claims, which begins on page 3.

Remarks begin on page 12.

EXPRESS MAIL LABEL NO. EV510808334US
DATE OF DEPOSIT: March 3, 2005

Amendments to the Specification

Please replace the paragraph beginning at page 1, line 3, immediately following the title, with the following rewritten paragraph:

-- PRIORITY CLAIM

This is the § 371 U.S. National Stage of International Application No.

PCT/US2003/028282, filed September 9, 2003, which was published in English under PCT

Article 21(2), which in turn claims the benefit of U.S. Provisional Application No. 60/409,742, filed September 10, 2002, which is incorporated by reference in its entirety.—

Please insert the attached Abstract as page 43 of the specification.

Claims

- 1. (original) A method for treating a subject having an infection caused by an Stx-producing organism by administering to the subject a therapeutically effective amount of hop bract tannin.
- 2. (original) The method of claim 1 further comprising administering to the subject a therapeutically effective amount of an antibiotic, the antibiotic being effective to treat an infection with the Stx-producing organism.
- 3. (original) The method of claim 2, wherein the antibiotic is selected from the group consisting of cefixime, tetracycline, ciprofloxacin, co-trimoxazole, norfloxacin, ofloxacin, fosfomycin and kanamycin and combinations thereof.
- 4. (original) The method of claim 1, wherein the hop bract tannin comprises a catechin polymer.
- 5. (original) The method of claim 4, wherein the catechin polymer comprises a polycatechin between a 10-mer and a 30-mer.
 - 6. (original) The method of claim 1, wherein the infection is an enteric infection.
- 7. (original) The method of claim 6, wherein the hop bract tannin is administered enterically.

8. (original) The method of claim 5 where the polycatechin has the formula

where n=8 to 28.

9. (original) The method of claim 5 where the polycatechin has the formula

where n = 8 to 28.

10. (original) The method of claim 1, wherein the hop bract tannin comprises a fraction isolated from a hop bract extract.

- 11. (original) The method of claim 10, wherein the fraction has a weight-average molecular mass between 5kDa and 30 kDa.
- 12. (original) The method of claim 1, wherein the Stx-producing organism comprises an Stx1-producing organism.
- 13. (original) The method of claim 1, wherein the Stx-producing organism is a Shiga toxin-producing Eschericia coli.
- 14. (original) The method of claim 1, wherein the infection is an enteric infection, and the hop bract tannin comprises a polycatechin between a 10-mer and a 30-mer, which is administered enterically.
- 15. (original) The method of claim 14, wherein the infection presents clinically as severe diarrhea, hemorrhagic colitis, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

16. (canceled)

17. (currently amended) A method of treating a subject having an infection of an Staproducing organism, comprising The method of claim 1, wherein administering to the subject a therapeutically effective amount of hop bract tannin comprises:

selecting a hop bract tannin having an affinity for an Stx produced by the Stx-producing organism; and

administering the hop bract tannin to the subject enterically in an amount effective to alleviate a clinical presentation of the infection.

18. (original) The method of claim 17, wherein selecting comprises isolating hop bract tannin from a hop bract extract by affinity chromatography with a chromatographic matrix derivatized with the Stx.

- 19. (original) The method of claim 17, wherein selecting comprises obtaining a high molecular weight fraction of a hop bract extract.
- 20. (original) The method of claim 19, wherein the high molecular weight fraction has a weight-average molecular weight of 5 kDa or greater.
- 21. (original) The method of claim 17, wherein selecting comprises detecting a hop bract tannin component having an affinity for the Stx.
- 22. (currently amended) The method of claim 21, wherein detecting a component having an affinity for the Stx comprises detecting a signal generated by a biosensor, the biosensor having a hop bract tannin as the <u>a</u> bioreceptor portion of the biosensor.
 - 23. (original) The method of claim 22 where the hop bract tannin is a polycatechin.
- 24. (original) The method of claim 23 where the polycatechin is between a 10-mer and a 30-mer polycatechin.
 - 25. 26. (canceled)
- 27. (original) The method of claim 17, wherein the clinical presentation of the infection is one or more of severe diarrhea, hemorrhagic colitis, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.
 - 28. (canceled)
- 29. (original) A method for detecting the presence of an Stx in a biological sample, comprising:

contacting the biological sample with a hop bract tannin; and detecting a macromolecular complex between the Stx and the hop bract tannin.

Page 6 of 12

- 30. (original) The method of claim 29, wherein detecting comprises detecting a precipitate comprising the complex.
- 31. (original) The method of claim 29, wherein detecting the macromolecular complex between the hop bract tannin and the Stx comprises detecting an electrophoretic pattern associated with the presence of the macromolecular complex in the sample.
- 32. (original) The method of claim 29, wherein the hop bract tannin serves as a bioreceptor of a biosensor and detecting comprises measuring a change in a property of a transducer of the biosensor.
- 33. (original) The method of claim 29, wherein the hop bract tannin is a polycatechin between a 10-mer and a 30-mer.
 - 34. (original) The method of claim 29, wherein the polycatechin has the forumla

where n = 8 to 28, or

where n = 8 to 28.

- 35. (original) The method of claim 29, wherein the hop bract tannin comprises a fraction isolated from a hop bract extract.
- 36. (original) The method of claim 35, wherein the fraction has a weight-average molecular mass between 5kDa and 30 kDa.
- 37. (currently amended) A method for isolating and purifying Stx-binding polyphenols, comprising:

contacting a mixture comprising [an]a Stx-binding polyphenolic compound isolated from *Humulus lupulus* with an Stx to form a macromolecular complex between the compound and the Stx;

isolating the macromolecular complex; and

separating the polyphenolic compound from the macromolecular complex to obtain a purified sample of the polyphenolic compound that binds Stx.

38. (original) The method of claim 37, wherein the Stx is coupled to an activated chromatographic matrix.

- 39. (original) The method of claim 37, wherein the Stx comprises he bioreceptor of a biosensor.
 - 40. (original) The method of claim 38, wherein the Stx is Stx1.
- 41. (original) A method for prophylatic or post-exposure treatment of an inhaled Stx comprising administering a therapeutically effective amount of hop bract tannin intranasally to a subject.
 - 42. (original) A biosensor, comprising: a hop bract tannin as a bioreceptor, and a transducer.
- 43. (original) The biosensor of claim 42, wherein the hop bract tannin is a polycatechin between a 10-mer and a 30-mer.
 - 44. (original) The method of claim 43, wherein the polycatechin has the forumla

where n = 8 to 28, or

where n = 8 to 28.

- 45. (original) The method of claim 42, wherein the hop bract tannin comprises a fraction isolated from a hop bract extract.
- 46. (original) The method of claim 45, wherein the fraction has a weight-average molecular mass between 5kDa and 30 kDa.

47.-57. (canceled)

- 58. (original) A method for neutralizing a bacterial toxin, comprising: providing a hop bract tannin; and contacting the bacterial toxin with the hop bract tannin to neutralize the toxin.
- 59. (original) The method of claim 58, wherein the bacterial toxin is selected from the group consisting of Shiga toxins and cholera toxins.
- 60. (original) The method of claim 58, wherein the hop bract tannin comprises a subfraction having a weight-average molecular weight from 5 kDa to 30 kDa.

EXPRESS MALE LABEL NO. EV510808334US DATE OF DEPOSIT: March 3, 2005

- 61. (original) The method of claim 58, wherein the hop bract tannin comprises a polycatechin selected from the group of 10-mers to 30-mers, and mixtures thereof.
- 62. (original) An isolated polyphenolic component of a high molecular weight fraction of a hop bract extract, the high molecular weight fraction having a weight average molecular weight of greater than 5 kDa.
- 63. (original) A subfraction of a high molecular weight fraction of a hop bract extract, the high molecular weight fraction having a weight average molecular weight of greater than 5 kDa.
- 64. (original) The subfraction of claim 63, wherein the subfraction has a weight average molecular weight range selected from the group consisting of 5 kDa-30kDa, 5kDa-10kDa, 5kDa-8kDa, 8kDa-30kDa, 8kDa-10kDa and 10kDa-30kDa.

Remarks

By this Amendment the specification has been amended to reflect prior related applications and to add an abstract on a separate page.

Claims 16, 26, 28 and 47-57 have been canceled, solely to reduce the filing fee and not for reasons of patentability. Claim 25 was inadvertently not included in the parent PCT application. To conform with the requirements of U.S. patent practice, claim 25 is indicated to be canceled. Claims 22 and 37 have been amended to correct matters of form. Claim 17 has been amended to be in dependent form, solely to reduce the filing fee.

The present application is being filed with a reduced filing fee under 37 CFR 1.492(a)(4), because the international preliminary examination fee was paid to the United States Patent and Trademark Office, and the international preliminary examination report (IPER) stated that the criteria of novelty, inventive step (non-obviousness), and industrial applicability, as defined in PCT Article 33(1)-(4), have been satisfied for all the claims presented in the application entering the national stage. As the claim amendments were made solely to reduce the filing fee, and to correct matters of form, Applicants believe that they are entitled to the reduced fee. If the United States Patent and Trademark Office determines that the standard filing fee is due, please charge this fee to Deposit Account No. 02-4550.

No new matter has been added by this Amendment.

Conclusion

If any minor matters remain to be resolved before examination of this application, please call the undersigned at the telephone number listed below.

Respectfully submitted.

KLARQUIST SPARKMAN, JAP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300

Facsimile: (503) 228-9446

and the second of the second o

ABSTRACT

FACTORS THAT BIND INTESTINAL TOXINS

Methods for neutralizing bacterial toxins such as Shiga toxins and cholera toxins are disclosed. In a particular embodiment, a method is provided for treating a subject suffering from an infection caused by an Stx-producing organism by administering a therapeutically effective amount of a hop bract tannin obtained from Humulus lupulus. Also provided are methods for isolating polyphenolic compounds that bind Stx molecules, and methods for detecting the presence of Stx molecules in a biological sample. In a disclosed embodiment, a subject infected with a Shiga toxin-producing E. coli strain is treated by enterically administering a high molecular weight fraction of hop bract extract to the subject.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
"

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.